These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 33407044

  • 1. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T, Doerler M, Scheel CH.
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract] [Full Text] [Related]

  • 2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW, Zachariae C, Simonsen AB.
    Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
    [No Abstract] [Full Text] [Related]

  • 3. Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab.
    Pogorelov D, Strotkötter H, Bjelic-Radisic V, Wesselmann U, Hübinger J, Sabulyte S, Hofmann SC, Balakirski G.
    Acta Derm Venereol; 2024 Sep 30; 104():adv40801. PubMed ID: 39347691
    [No Abstract] [Full Text] [Related]

  • 4. Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor.
    Takeda K, Nakano K, Udagawa S, Fukuda N, Nishizawa A, Ono M, Urasaki T, Tomomatsu J, Mochizuki T, Shiga T, Kogawa T, Takahashi S, Kitano S.
    Rheumatology (Oxford); 2021 Dec 24; 61(1):e13-e14. PubMed ID: 34463707
    [No Abstract] [Full Text] [Related]

  • 5. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP, Cardones AR.
    Br J Dermatol; 2019 Sep 24; 181(3):580-583. PubMed ID: 30244487
    [Abstract] [Full Text] [Related]

  • 6. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.
    Ogawa-Momohara M, Muro Y, Goto K, Obuse C, Satoh M, Kono M, Akiyama M.
    J Dermatol; 2020 Jun 24; 47(6):e217-e219. PubMed ID: 32173880
    [No Abstract] [Full Text] [Related]

  • 7. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun 24; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 8. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
    Canale ML, Camerini A, Casolo G, Lilli A, Bisceglia I, Parrini I, Lestuzzi C, Del Meglio J, Puccetti C, Camerini L, Amoroso D, Maurea N.
    Adv Ther; 2020 Jul 24; 37(7):3178-3184. PubMed ID: 32436027
    [Abstract] [Full Text] [Related]

  • 9. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S, Shiraishi K, Mito T, Sayama K.
    Clin Exp Dermatol; 2020 Oct 24; 45(7):908-911. PubMed ID: 32394515
    [No Abstract] [Full Text] [Related]

  • 10. Pembrolizumab in the Treatment of Breast Cancer.
    Pivot X.
    N Engl J Med; 2022 Jul 21; 387(3):273-274. PubMed ID: 35857664
    [No Abstract] [Full Text] [Related]

  • 11. Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
    Figueredo Zamora E, Callen JP, Schadt CR.
    Lupus; 2021 Apr 21; 30(4):661-663. PubMed ID: 33349110
    [Abstract] [Full Text] [Related]

  • 12. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing.
    Nasser R, Fisher Y, Klein A.
    J Gastroenterol Hepatol; 2021 Oct 21; 36(10):2639. PubMed ID: 33624341
    [No Abstract] [Full Text] [Related]

  • 13. Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review.
    Diago A, Hueso L, Ara-Martín M, Abadías-Granado I.
    Australas J Dermatol; 2021 May 21; 62(2):e347-e349. PubMed ID: 33484581
    [No Abstract] [Full Text] [Related]

  • 14. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 May 21; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 15. IgA nephropathy after pembrolizumab therapy for mesothelioma.
    Wang R, Das T, Takou A.
    BMJ Case Rep; 2020 Nov 30; 13(11):. PubMed ID: 33257374
    [Abstract] [Full Text] [Related]

  • 16. Subacute cutaneous lupus erythematosus induced by nivolumab.
    Liu RC, Sebaratnam DF, Jackett L, Kao S, Lowe PM.
    Australas J Dermatol; 2018 May 30; 59(2):e152-e154. PubMed ID: 28726325
    [No Abstract] [Full Text] [Related]

  • 17. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation.
    Bui AN, Hirner J, Singer SB, Eberly-Puleo A, Larocca C, Lian CG, LeBoeuf NR.
    Clin Exp Dermatol; 2021 Mar 30; 46(2):328-337. PubMed ID: 32939795
    [Abstract] [Full Text] [Related]

  • 18. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
    Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GV.
    N Engl J Med; 2022 Apr 28; 386(17):1668-1669. PubMed ID: 35476655
    [No Abstract] [Full Text] [Related]

  • 19. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S, Li X, Nong J, Zhang Y.
    Zhongguo Fei Ai Za Zhi; 2020 Aug 20; 23(8):685-688. PubMed ID: 32752585
    [Abstract] [Full Text] [Related]

  • 20. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
    Kosche C, Owen JL, Choi JN.
    Dermatol Online J; 2019 Oct 15; 25(10):. PubMed ID: 31735010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.